Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 15/20 | 0.77 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flortaucipir F 18 SCHEMBL13640613 | 1.00 | MAPT (0.77) | MAPTACHEKIF11CHUK | |
| Flortaucipir F 18 SCHEMBL29379518 | 1.00 | MAPT (0.77) | MAPTACHEKIF11CHUK | |
| Flortaucipir SCHEMBL29439901 | 1.00 | MAPT (0.77) | MAPTACHEKIF11CHUK | |
| Flortaucipir SCHEMBL14053964 | 1.00 | MAPT (0.77) | MAPTACHEKIF11CHUK | |
| Flortaucipir SCHEMBL29773835 | 1.00 | MAPT (0.77) | MAPTACHEKIF11CHUK | |
| Flortaucipir SCHEMBL29548430 | 1.00 | MAPT (0.77) | MAPTACHEKIF11CHUK | |
| SCHEMBL21217176 | 0.87 | MAPT (1.00) | MAPTACHEKIF11 | |
| SCHEMBL17997396 | 0.84 | MAPT (0.63) | MAPTACHEKIF11 | |
| SCHEMBL20128568 | 0.84 | MAPT (0.63) | MAPTACHEKIF11CHUK | |
| SCHEMBL22906721 | 0.83 | MAPT (0.66) | MAPTACHEKIF11CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132190-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | ELI LILLY AND CO (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260125460-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | LILLY CO ELI (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250296997-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | ELI LILLY AND COMPANY | 2025-09-25 | — | — | US | disclosed |
| US-20250064417-A1 | REGIONAL TAU IMAGING FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY | 2025-02-27 | — | — | US | disclosed |
| EP-4472679-A1 | REGIONAL TAU IMAGING FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE | Eli Lilly and Company (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240309082-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | ELI LILLY AND COMPANY | 2024-09-19 | — | — | US | disclosed |
| EP-4423128-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | Eli Lilly and Company (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4423127-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | Eli Lilly and Company (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4422751-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | Eli Lilly and Company (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4423129-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | Eli Lilly Company (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076995-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | ELI LILLY AND COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076971-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | ELI LILLY COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023077042-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | ELI LILLY AND COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023070064-A1 | O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023036936-A1 | BIFUNCTIONAL MOLECULES AS PROTEASOME STIMULATORS FOR IMPROVED TARGETED PROTEIN DEGRADATION, AND THEIR USES AS TARGETED BOOSTING DEGRADERS (TARBODS) | BOOSTER THERAPEUTICS GMBH (DE) | 2023-03-16 | — | — | WO | disclosed |
| EP-4147723-A1 | BIFUNCTIONAL MOLECULES AS PROTEASOME STIMULATORS FOR IMPROVED TARGETED PROTEIN DEGRADATION, AND THEIR USES AS TARGETED BOOSTING DEGRADERS (TARBODS) | Booster Therapeutics GmbH (DE) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022251048-A1 | ANTI-AMYLOID BETA ANTIBODIES AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022192639-A2 | ANTI-N3PGLU AMYLOID BETA ANTIBODIES AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022192636-A1 | ANTI-AMYLOID BETA ANTIBODIES AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022150735-A1 | ANTI-N3PGLU AMYLOID BETA ANTIBODIES AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132190-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | IL36G, IL33, BACE1 | MAPT 8/4885ACHE 1237/4885KIF11 3258/4885 |
| US-20260125460-A1 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | IL36G, IL33, BACE1 | MAPT 8/4885ACHE 1237/4885KIF11 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.